Tumor Cell/Dendritic Cell Interactions and the Influence of Tumors on Dendritic Cell-mediated Anti-Tumor Immune Responses and Dendritic Cell-Based Tumor Immunotherapies.

Tumor Cell/Dendritic Cell Interactions and the Influence of Tumors on Dendritic Cell-mediated Anti-Tumor Immune Responses and Dendritic Cell-Based Tumor Immunotherapies.

Saved in:
Bibliographic Details
Author / Creator:Kristian Michael Hargadon.
Imprint:Frontiers Media SA 2014.
Description:1 electronic resource (160 pages)
Language:English
Series:Frontiers Research Topics,
Subject:
Medicine (General)
Immunologic diseases. Allergy.
Neoplasms. Tumors. Oncology. Including cancer and carcinogens.
Dendritic cells.
Tumors.
Format: E-Resource Book
URL for this record:http://pi.lib.uchicago.edu/1001/cat/bib/12328396
Hidden Bibliographic Details
Other uniform titles:Directory of open access books.
Other authors / contributors:Timothy Bullock.
ISBN:9782889192458
2889192458
Notes:Includes bibliographical references.
English.
Summary:Significant efforts over the last two decades have been made to better understand the factors that control DC maturation and activation and the impact of these processes on overall host immunity. In addition to the well-characterized role of DC in the induction of immunity to pathogens, a role for these cells as critical regulators of anti-tumor immune responses has more recently become apparent. These findings have generated interest in understanding how tumor/DC interactions impact the quality of anti-tumor immune responses, and they have contributed to increased enthusiasm for a variety of DC-based cancer immunotherapies. Such strategies have included DNA- or peptide-based vaccines that involve uptake and processing of tumor antigens by endogenous DC in cancer patients or the administration of tumor antigen-loaded exogenous DC-based vaccines. Additionally, many adjuvant, cytokine, and monoclonal antibody therapies aim either to enhance the immunostimulatory capacity of endogenous DC or to supplement the activity of these cells by targeting costimulatory receptors on T cells. Despite the promise of such therapeutic approaches for cancer treatment, their success is often limited, and much remains to be understood about how tumors influence DC function and the quality of DC-mediated immune responses. Tumor/DC interactions have therefore become an increasingly active area of investigation, and many studies have described effects of tumors on DC phenotype and function that include an accumulation of immature DC within tumors, tumor-altered differentiation of DC precursors into myeloid-derived suppressor cells, and the generation of tumor-associated DC with immunoregulatory properties. As this field moves forward, it will be important to gain mechanistic insights into the basis for both tumor-mediated DC dysfunction as well as the induction of either suboptimal or immunosuppressive adaptive anti-tumor immune responses by tumor-associated DC. Progress in these areas of tumor immunology will greatly improve our understanding of the factors that contribute to effective DC-mediated anti-tumor immune control versus DC-associated anti-tumor immune dysfunction and subsequent tumor immune escape. Such information is vital for improving current and developing novel immunotherapeutic strategies for interfering with tumor-associated DC dysfunction and enhancing the functional quality of endogenous DC in cancer patients as well as the efficacy of exogenous DC-based anti-tumor vaccines. The articles contained within this special issue highlight these important topics and bring focus not only to our current understanding of tumor/DC interactions but also to major areas of investigation that remain ongoing in this field.
Other form:Print version: Tumor cell/dendritic cell interactions and the influence of tumors on dendritic cell-mediated anti-tumor immune responses and dendritic cell-based tumor immunotherapies. [Lausanne, Switzerland] : Frontiers Media SA, 2014 9782889192458

MARC

LEADER 00000cam a2200000Mu 4500
001 12328396
005 20220624111547.0
006 m o d
007 cu uu||||uuuu|
008 151116s2014 xx o 000 u eng d
019 |a 1096803879 
020 |a 9782889192458 
020 |a 2889192458 
035 |a (OCoLC)945783020  |z (OCoLC)1096803879 
035 9 |a (OCLCCM-CC)945783020 
040 |a SFB  |b eng  |c SFB  |d OCLCQ  |d WY@  |d VT2  |d WYU  |d AU@  |d OCLCF 
049 |a MAIN 
050 4 |a QR185.8.D45 
100 1 |a Kristian Michael Hargadon.  |4 aut 
245 1 0 |a Tumor Cell/Dendritic Cell Interactions and the Influence of Tumors on Dendritic Cell-mediated Anti-Tumor Immune Responses and Dendritic Cell-Based Tumor Immunotherapies. 
260 |b Frontiers Media SA  |c 2014. 
300 |a 1 electronic resource (160 pages) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
490 0 |a Frontiers Research Topics, 
520 |a Significant efforts over the last two decades have been made to better understand the factors that control DC maturation and activation and the impact of these processes on overall host immunity. In addition to the well-characterized role of DC in the induction of immunity to pathogens, a role for these cells as critical regulators of anti-tumor immune responses has more recently become apparent. These findings have generated interest in understanding how tumor/DC interactions impact the quality of anti-tumor immune responses, and they have contributed to increased enthusiasm for a variety of DC-based cancer immunotherapies. Such strategies have included DNA- or peptide-based vaccines that involve uptake and processing of tumor antigens by endogenous DC in cancer patients or the administration of tumor antigen-loaded exogenous DC-based vaccines. Additionally, many adjuvant, cytokine, and monoclonal antibody therapies aim either to enhance the immunostimulatory capacity of endogenous DC or to supplement the activity of these cells by targeting costimulatory receptors on T cells. Despite the promise of such therapeutic approaches for cancer treatment, their success is often limited, and much remains to be understood about how tumors influence DC function and the quality of DC-mediated immune responses. Tumor/DC interactions have therefore become an increasingly active area of investigation, and many studies have described effects of tumors on DC phenotype and function that include an accumulation of immature DC within tumors, tumor-altered differentiation of DC precursors into myeloid-derived suppressor cells, and the generation of tumor-associated DC with immunoregulatory properties. As this field moves forward, it will be important to gain mechanistic insights into the basis for both tumor-mediated DC dysfunction as well as the induction of either suboptimal or immunosuppressive adaptive anti-tumor immune responses by tumor-associated DC. Progress in these areas of tumor immunology will greatly improve our understanding of the factors that contribute to effective DC-mediated anti-tumor immune control versus DC-associated anti-tumor immune dysfunction and subsequent tumor immune escape. Such information is vital for improving current and developing novel immunotherapeutic strategies for interfering with tumor-associated DC dysfunction and enhancing the functional quality of endogenous DC in cancer patients as well as the efficacy of exogenous DC-based anti-tumor vaccines. The articles contained within this special issue highlight these important topics and bring focus not only to our current understanding of tumor/DC interactions but also to major areas of investigation that remain ongoing in this field. 
546 |a English. 
504 |a Includes bibliographical references. 
650 0 |a Medicine (General) 
650 0 |a Immunologic diseases. Allergy. 
650 0 |a Neoplasms. Tumors. Oncology. Including cancer and carcinogens. 
650 7 |a Dendritic cells.  |2 fast  |0 (OCoLC)fst00890269 
650 7 |a Tumors.  |2 fast  |0 (OCoLC)fst01158759 
653 |a tumor 
653 |a dendritic cell 
653 |a cancer immunotherapy 
653 |a tumor immune evasion 
653 |a cross-presentation 
653 |a Immune Regulation 
730 0 |a Directory of open access books. 
700 1 |a Timothy Bullock.  |4 aut 
776 0 8 |i Print version:  |t Tumor cell/dendritic cell interactions and the influence of tumors on dendritic cell-mediated anti-tumor immune responses and dendritic cell-based tumor immunotherapies.  |d [Lausanne, Switzerland] : Frontiers Media SA, 2014  |z 9782889192458 
856 4 0 |u https://directory.doabooks.org/handle/20.500.12854/61391  |y Open Access Publishing in European Networks 
901 |a OpenAccess 
903 |a HeVa 
929 |a oclccm 
999 f f |i 0d3ae313-39f1-5d74-b0ee-7a3a81ba5ead  |s 774d7ed6-f47e-5bbf-9539-6e93d880b4ac 
928 |t Library of Congress classification  |a QR185.8.D45  |l Online  |c UC-FullText  |u https://directory.doabooks.org/handle/20.500.12854/61391  |z Open Access Publishing in European Networks  |g ebooks  |i 11895092 

Similar Items